Viabahn腔内人工血管治疗髂股动脉长段闭塞性病变的疗效评价

doi:10.13481/j.1671-587x.20160331

Abstract

Abstract:

Objective: To discuss the experiences and therapeutic effects of Viabahn endovascular treatment in transluminal vascular occlusive disease of long segment of iliac-femoral artery,and to evaluate its curative effect in occlusive disease of peripheral artery. Methods: The clinical data of total 78 patients (89 lower limb) with transluminal vascular occlusive disease of long segment of iliac-femoral artery were collected and the patients were divided into bare stent group (42 cases,48 lower limb) and Viabahn group (36 cases,41 lower limb).The general information,peri-operative and long-term patency rate,and rate of limb salvage of patients in two groups were collected.The follow-up time was 3-12 months and the average follow-up time was 11.08 months. Results: Compared with before operation,the ischemic symptoms of the patients in two groups after operation were improved and the ankle brachia index(ABI) was increased(P<0.05).3,6,and 9 months after post-operative follow-up,the primary and secondary patency rates of the patients in two groups showed no significant difference (P>0.05).12 months after post-operative follow-up,the primary and secondary patency rates of the patients in Viabahn group were higher than those in bare stent group (P<0.05).The 1-year limb salvage rates of patients in two groups were 100%.The patients in bare stent group had more risk to suffer stent thrombosis than those in Viabahn group (P<0.05). Conclusion: Using Viabahn for treatment of transluminal vascular occlusive disease of long segment of iliac-femoral artery (≥10 cm) is safe and effective,and the 12-month long-term patency rate and the risk to suffer stent thrombosis are superior to bare stent.

Key words: arterial occlusive disease, iliac artery, femoral artery, artificial vessel, stent

CLC Number:

R654.4

WANG Shuai, SeanX.LUO, SUN Siqiao, CHENG Zhihua, ZHANG Yang, ZHAO Wenguang, WANG Qi. Evaluationon curative effect of Viabahn endovascular treatment in transluminal vascular occlusive disease of long segment of iliac-femoral artery[J].Journal of Jilin University Medicine Edition, 2016, 42(03): 577-581.

References

[1] Henry M,Rath PC,Klonaris C,et al.Peripheral vascular diseases:an update on endovascular therapy[J].Indian Heart J,2005,57(6):747-766.

[2] Dake MD.Abstract No.10:Zilver PTX randomized trial of paclitaxel-eluting stents for femoropopliteal artery disease:24-month update[J].J Vase Interv Radiol,2011,22(3):S7-S8.

[3] McQuade K,Gable D,Hohman S,et al.Randomized comparison of ePTFE/nitinol self-expanding stent graft vs prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease[J].J Vasc Surg,2009,49(1):109-115.

[4] Gorgani F,Telis A,Narakathu N,et al.Long-term outcomes of the Viabahn stent in the treatment of in-stent restenosis in the superficial femoral artery[J].J Invasive Cardiol,2013,25(12):670-674.

[5] Kazemi S,Djelmami-Hani M,Tumuluri R,et al.VIABAHN stent-graft for treatment of in-stent restenosis in femoropopliteal vascular occlusive disease,procedural outcome and one-year follow-up[J].Am J Cardiol,2006,98(2):236.

[6] 温志国,杜丽苹,李文明,等.TASC C D型下肢动脉硬化闭塞症的腔内治疗[J].中华普通外科杂志,2014,29(1):29-31.

[7] 赵俊来,李伟,张小明,等.主髂动脉闭塞的覆膜支架介入治疗[J].中华普通外科杂志,2013,28(7):507-510.

[8] Saxon RR,Chervu A,Jones PA,et al.Heparin-bonded,expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease:1-year results of the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) trial[J].J Vasc Interv Radiol,2013,24(2):165-173.

[9] 倪冷,李拥军,郑月宏,等.主髂动脉病变腔内治疗并发症的预防与处理[J].中华普通外科杂志,2015,30(6):440-443.

[10] Sixt S,Krankenberg H,Mohrle C,et al.Endovascular treatment for extensive aortoiliac artery reconstruction:a single-center experience based on 1712 interventions[J].J Endovasc Ther,2013,20(1):64-73.

[11] 孙占国,张小明,张学民,等.主髂动脉病变腔内治疗术中髂动脉破裂的处理[J].中华普通外科杂志,2015,30(7):509-512.

[12] Saxon RR,Coffman JM,Gooding JM,et al.Long-term patency and clinical outcome of the Viabahn stent-graft for femoropopliteal artery obstructions[J].J Vasc Interv Radiol,2007,18(11):1341-1349.

[13] Laird JR,Katzen BT,Scheinert D,et al.Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery:twelve-month results from the RESILIENT randomized trial[J].Circ Cardiovasc Interv,2010,3(3):267-276.

[14] Tepe G,Zeller T,Albrecht T,et al.Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg[J].N Engl J Med,2008,358(7):689-699.

[15] Werk M,Langner S,Reinkensmeier B,et al.Inhibition of restenosis in femoropopliteal arteries:paclitaxel-coated versus uncoated balloon:femoral paclitaxel randomized pilot trial[J].Circulation,2008,118(13):1358-1365.

[16] 郝良玉,庄百溪,张童,等.Viabahn腔内人工血管治疗股浅动脉狭窄闭塞性病变[J].中华普通外科杂志,2014,29(10):760-762.

[17] 宋庆宏,李阳春,赵奇,等.VIABAHN支架治疗下肢动脉闭塞的效果分析[J].天津医药,2014,42(8):825-827.

Evaluationon curative effect of Viabahn endovascular treatment in transluminal vascular occlusive disease of long segment of iliac-femoral artery

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 12

Metrics

Comments

Recommended 10

[1]	CUI Yan, SHI Yongfeng, GUO Ziyuan, LIU Bin, WANG Jinpeng, ZHAO Lei, WANG Junnan, PIAO Jinhua. Application of intravascular ultrasound in analysis on influencing factors of prognosis in patients with different coronary artery in-stent restenosis [J]. Journal of Jilin University Medicine Edition, 2016, 42(04): 746-752.
[2]	WANG Xiao-qing,WANG Chun-xi,HOU Yu-chuan,CHEN Qi-hui,ZHANG Hai-feng,JIANG Feng-m. Preparation and mechanical properties of co-polymer poly(lactic-co-glycolic acid) \|degradable tubular urethral scaffold [J]. J4, 2012, 38(1): 33-36.
[3]	LIU Ya-Min, HAN Hui, QIN Hao, YU Li, ZHANG Min, FENG Jun. Evaluation of curative effect of interventional therapy for chronic simple atherosclerotic occlusive disease of lower extremity [J]. J4, 2011, 37(1): 122-126.
[4]	WANG Zhi-Hui, ZHANG Jing, XING Yue. Effect of Kudiezi injection on stent thrombosis and matrix metalloproteinase in patients with PCI [J]. J4, 2010, 36(2): 377-380.
[5]	LIU Tong-jun， JIANG Wei， YU Hui-qiu，JING Xia-bin，CHEN Xue-si，LI Jan-guo，LI Peng-fei. Feasibility and safety of repairing dog common bile duct with laser welding assisted with chemical glue following placing degradable stent in it [J]. J4, 2007, 33(3): 449-453.
[6]	HOU Yu-chuan,WANG Chun-xi,CHEN Xue-si, ZHANG Bao-gang. Ureteral in situ biocompatibility of L-lactide-glycolic acid copolymer 80∶20 stent [J]. J4, 2006, 32(5): 762-765.
[7]	WANG Zhi-hui，LI Shu-mei，XING Yue. Clinic efficacy of Cypher^TM stent and bare stent in elderly patients with acute myocardial infarction [J]. J4, 2006, 32(4): 694-697.
[8]	ZHANG Kai, LIU Tong-jun, JING Xia-bin, CHEN Xue-si, LI Jian-guo, LI Peng-fei. Degradation of polylactic acid/glycolic acidstents in bile in vitro [J]. J4, 2005, 31(6): 909-911.
[9]	SHEN Zhen, LIU Tong-jun, JING Xia-bin,CHEN Xue-si, XU Xiao-yi, LI Jian-guo, LI Peng-fei. Feasibility of placing degradable stent in CBD and laser weldingafter CBDE in dogs and histological changes of CBD [J]. J4, 2005, 31(5): 678-680.
[10]	HOU Yu-chuan,WANG Chun-xi,ZHENG Zuo-zhu，WANG Yan,ZHAO Zhong-wen. Biocompatibility and biodegradation characteristics of poly(L-lactide-co-glycolide) in vivo and in vitro [J]. J4, 2005, 31(4): 526-529.
[11]	SUN Ji-hong，LI Shu-mei，ZHANG Dan, FEI Yu，LI Rui. Effects of Panax Notoginseng Saponins on P-selectin, tissue-type plasmiogen activitor and plasminoge activitor inhibitor-1 levels in patients with acute coronary syndrome after intracoronarystent implantation [J]. J4, 2005, 31(2): 306-308.
[12]	HOU Yu-chuan,WANG Chun-xi,LI Na. Biocompatibility and biodegradation of poly (caprolactone-b-ethylene oxide) in vivo and in vitro [J]. J4, 2004, 30(3): 362-365.